BioCentury | Jun 26, 2019
Distillery Therapeutics

RTN4 and S1PR2 identified as targets for stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke A team led by NovaGo Therapeutics co-founder Martin Schwab showed inhibition of RTN4 or its receptor S1PR2 could help treat stroke. In mice, levels of RTN4 and S1PR2 were elevated...
BioCentury | May 15, 2018
Distillery Therapeutics


INDICATION: Spinal cord injury (SCI) Cell culture and mouse studies suggest antagonizing OPRL1 alone or in combination with inhibiting its downstream effector RTN4R could help treat SCI. In primary mouse cortical neurons subjected to scrape...
BioCentury | Nov 30, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2017

...School of Public Health Preclinical News Infectious disease Dengue fever; West Nile virus; Zika virus Reticulon 3...
BioCentury | Nov 27, 2017
Distillery Therapeutics

Infectious disease

...identifying and testing RTN3 inhibitors in models of dengue fever, West Nile and Zika. TARGET/MARKER/PATHWAY: Reticulon 3... the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia email: Hongjiang Li University of Melbourne Reticulon 3...
BioCentury | Jan 11, 2017
Distillery Therapeutics


INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of Nogo...
BioCentury | Jan 7, 2016


TECHNOLOGY: Fluorescence labeling of corticospinal tract axons to monitor axon regeneration following spinal cord injury (SCI) Fluorescence labeling of corticospinal tract axons could help screen for molecular targets involved in promoting axon regeneration after SCI....
BioCentury | Jul 17, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; stroke Reticulon 4 (RTN4; NOGO-A; NOGO; NOGO-B) Rat studies suggest treatment with NOGO-A inhibitors followed by physical therapy could help improve motor recovery...
BioCentury | Jul 29, 2013
Company News

GlaxoSmithKline neurology news

GlaxoSmithKline said in a statement on July 22 that senior GSK executives in China "appear to have acted outside of our processes and controls which breaches Chinese law." Earlier this month, the pharma said it...
BioCentury | Jan 21, 2013
Product Development

Solving the ALS maze

Three companies with Phase II data for amyotrophic lateral sclerosis believe they have identified at least two ways to improve the odds of clinical success, even though the disease has poorly understood biology, heterogeneous presentation...
BioCentury | Dec 10, 2012
Company News

AlphaCore Pharma LLC, Axerion Therapeutics, Optimum Therapeutics LLC, NIH cancer, cardiovascular, neurology news

NIH selected three projects for 2012 to receive no-cost access to NIH development contractor resources under its Bridging Interventional Development Gaps (BrIDGs) program. The program aims to help projects from academic institutions, not-for-profits and Small...
Items per page:
1 - 10 of 30